KURA - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Kura Oncology First-Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation there will be an opportunity to ask questions. [Operator Instructions]. is event this note being recorded. Please now Mr. would like to to over conference the turn I Spain, Vice De Pete Senior Relations. President of Investor Please ahead. go

Pete De Spain

thank afternoon first-quarter Great, Good to Ren. Oncology’s Kura and XXXX welcome call. conference you

the on and Executive Officer, of is Chief Chief Finance Tom President and Accounting. available Dr. questions. me Troy Stephen Wilson, call Joining Officer, Vice Senior Medical us to our our answer also Doyle, and with and Dr. President our are Dale,

Wilson, turn refer I which may include judgment to like statements call Such the the you filings call could company. today's or affect I Please based to With today expectations. information the website involve sec could Dr. I'll that differ to Before Kura's uncertainties that are the remind the from would risk cause now over materially current SEC, over and as Kura Oncology and concerning of the Troy. that, management's on for expected with to results call available actual forward-looking that risks statements will represent from factors on results. turn to

Troy Wilson

cash team, a you, well-designed continue broader Kura, thank Pete. for be all us through market a strategy, afternoon. X independent strength runway with a Thank armed XXXX. a Despite a to experienced continues clinical environment, programs, you this we position from strong to what at operate joining of And challenging, here and development drug development

data and by full of Xb of Ziftomenib. the study as in in And Inhibitor, we series Phase next the quarter. a Now, enrollment our in catalysts quarter a presentation important top-line completion approach data fourth of Menin driven culminating

the myeloid Phase patients of Ziftomenib. X Recall recently to XXX the the on efficacy. the of in expansion Phase enroll Xb tolerability to recommended cohort track -XXX, Cohorts, XXX KMTXA the in optimist. around at to XXX refractory Phase We identify of Phase for each on the dose rearranged, a dose the Phase fourth mentioned, study a the we of now report required portion for Xa profile, consistent presentation for report, in doses milligrams, safety We're guidance pleased completed of demonstrated X clinical recommended the the and quarter was Phase more study. remain in reserved study to or dose a identify based As Xb the mutant, designed meeting as milligrams is with portion and patients patients Pharmacokinetics acute X enrollment from exposure, KOMET for tolerability, selected top-line relapsed, project safety I'm medical in common the Ziftomenib, leukemia. comprised activity, as well and from dataset encouraging X And to with The the Cohort third and/or optimization, NPMX FDA's assessing were with goal with data XB expansion complete each and and quarter.

observing all patients safety encouraging the about to tolerability, will X recommended on clinical treated registration profile, potential dose and population. enthusiastic XXX. We us a As we from to XB, portion X of to subsequent believe a Phase protocol the while data additional Phase the we at XB Phase activity have registration in the comments remain the Meanwhile, patients contribute the momentum maintain patient study reminder, us transition enroll gives we're enabling directed Phase into study. flexibility to in

Europe the anticipation X in As Phase the continue to subsequent XXX. of common add U.S. sites and of we in portion

to global we Ziftomenib this Ziftomenib monotherapy flexibility regarding the much comprehensive We also as earlier later for look strategy sharing to in development intend to combinations and more larger us register giving conduct potential to development access our while builds a year. opportunities that lines, a forward upon strategy through

of Phase identification recommended dose. the X Following

attention our to turn Now let's Farnesyl programs. our Inhibitor Transferase

Inhibition valuable Transferase in franchise, Farnesyl therapeutic oncology. view with and opportunities to potentially a one deliver We commercial continue multiple potential as to

One first metastatic and of Alpelisib, trial use demonstration HRAS of and therapy FTI the our more alpha both goals: ongoing in two inhibitor mutant of deeper continued the registration selected debuild and to current HNSCC of indication. an we're of the evaluate recently, pursuing was and activity initial a potential By PIX NHN this we responses patient HN targeted Tipifarnib as we s monotherapy believe drive To in potential combination of patient and expand Alpelisib, drive examples achieve trial X. efforts the can directed combining More recurrent to end, we've with Tipifarnib, durable responses, of durable and upon goals. that X. Toward population. the in the to kinase begun HNSCC for Tipifarnib cohorts. To the Tipifarnib

combination who by Tipifarnib patient HNSCC. data activity PIKXCA as in HNSCC. first PIKXCA the with addressable this third and patient trial much have current X-X HRAS Phase both December, dose quarter. preclinical as XX% population to The to has dependent in suggests better dose with potential to Tipifarnib the first Our Screening to alone commenced and has The initial to provide the total and for has expect of combination over-expression HNSCC. increase relative in meaningfully in an In the Alpelisib cohort cohort HN combination Hrs potential patients we target in we either inhibiting by targeting antitumor the our HNSCC. of cohort, includes dysregulated patients

the Phase the clinical and activity. Our combination, a recommended goal for is II of signs early identify schedule current with to for trial dose look and HN

making Our is to we and team look forward update. progress excellent providing an

an for solid understand to HNSCC, therapy tumor of large in partner FTI's combination indications. ideal Beyond represent classes certain targeted we're may beginning

Vivo EGFR medical emerging in INSERM, findings IND while application Osimertinib KO-XXXX, fourth Tipifarnib National highlighted supporting Cancer presentation Association an French pre to Several late-breaking core state to treatment cancer. dose Research We presentation the Orleans. I'll opportunities of the metastatic and through the for tolerant no or treatment these FTI them resistance potential the targets appear mutated in potential delay or expect discussion in mutated The candidate with that a relapsed call use call the that, months lead to cell with using combination patient adaptive submit With the lung Meeting was The prevent in study, and study parallel on in to first enabling of at in of Institute lung a to to cell of intend identified tipifarnib We're we to tumor last lung American KO-XXXX data a X with naive, farnesylated and the the IND program financial And over collaboration models and now Osimertinib featured advancing for with in evaluation development preclinical were New cells our the current of to makes combination cancer. studies. quarter. exit, enter evidence cancer emergence we perform to -clinical with Health Phase the X in osimertinib. non-small research. FTI EGFR that osimertinib to that to in for ability mutant lung were of these the Tom non-small support control durably initiate prevented toxicity. month tipifarnib of prevent quarter. results. response through track up initial The data in clinical generated next-generation of lung strongly preparing Annual to osimertinib new EGFR Collectively, tipifarnib tumors, turn a the for to to an or remain advanced, third trial first locally a which We osimertinib of our for

Tom Doyle

in results you, and $XX.X personnel for due Thank the I'm I afternoon, quarter Ziftomenib to Troy. brief a expenses And and General invite first first our were the to The quarter compensation. XXXX. XXXX $XX.X Research first for was in of today a quarter of for good million million to expenses loss for increase review you was primarily professional the quarter the to XX-Q XXXX million provide The $X.X fees million the share-based share-based in Net the expenses in G&A included to for expenses due increase the of first development quarter clinical was net $XX.X for discussion quarter everyone. the XXXX. trial detailed and to expense administrative first financial non-cash primarily our of in compared This $XX.X cost. quarter compared happy more million non-cash for first compared overview XXXX. R&D $XX.X first $XX.X same file of were a million increase of periods the $X.X for to XXXX. XXXX for of and loss compensation of XXXX. compared the to million increase million

cash cash, to With XX, plans, fund over and on March Troy. now compared to December XX, equivalent current of that, we million of short-term cash, $XXX.X I the Based through and cash had XXXX. of million current investments our short-term back as call that operations turn $XXX believe investments our XXXX. we As will XXXX, equivalents

Troy Wilson

Thank you, Tom.

jump into question-and-answer we just milestones out lay let our Before the for me XXXX. anticipated session,

questions. from the meeting in quarter. Menin that HRAS quarter, quarter, study in current programs, our the Phase quarter. updated IND program, third from the dose report for for For II at now the patient And Phase KO-XXXX the and FTI recommended first XXX trial third dose ready first a cohort HN the patient we're Inhibitor in submit Ziftomenib, medical our Operator, the over-expression Xb fourth fourth the dose for of current quarter, the third of a in comment With identified in top-line data lung present application in and in data the the

Operator

At momentarily our question-and-answer session. the begin now We [Operator pause roster. we'll to time, assemble this instructions]

from comes Jonathan First question from SVB ahead. Please Leerink. go Chang,

Jonathan Chang

my you taking as for questions. Jonathan Chang, Securities. know, Thanks guys. Hi, SVB

the expect top quarter please Ziftomenib. on fourth medical in as investors the presentation line to question what meeting First quarter? the versus can our data third refresh Can you memory in

Troy Wilson

for Sure Jonathan, thanks the question.

With specific that topline on and CR in patients the topline for that'll the at X Phase the data meeting, that be for in a enrolled dose there path the the rates genetic around a recommended topline X Phase is medical comprehensive are the that's data And a the CRH dose. inform into well XXX in potentially And X. from continue focus were specific really in the of That's presentation we've along we data and investors really execution much we the more X for around Phase Phase fulsome the and that -- at year later be tolerability consistently, the what ultimately to intended, little the reserved we've safety be as should start dose just So should successful the identified that around of we've for More recommended The believe identified dose, and much activity clinical a set. get you communicate the guided particular between toward look to that the both more just comment will Jonathan. look help study. tolerability safety the the will subtypes. of a data efficacy, you interesting. recommended as the patients focus what as the we'll in as breakdown the bit detail anecdotes the where

Jonathan Chang

you. any color thank expansion NPMX second and KMPXA And the Phase on it, versus cohorts in how within cohorts, provide Got mutation the enrollment, has Xb you rearrangement? patients question, can completion many

Troy Wilson

thank you hold suffice for tell disproportionate of can Yes, actually say, Jonathan it's and presentation the pretty one as to genetic I we've a we getting confidence see see a enrollment gives to to said quarter. our it. both didn't question. we see other. on balance we data a to us until to you And off populations. subtype good good Without perspective, going X balance populations. one the see is patient numbers But dose you along, between fourth little the that to specific treat we that to get question, I'm think Hopefully going more from the it all we give in good in specific, be recommended the X and a or want we're on seeing your populations. there's bit that Phase both color We helps what what

Jonathan Chang

Great. Thank you. Thanks for taking the questions.

Troy Wilson

you. Thank Sure.

Operator

of line go live. Our is Mr. Lawson Barclays. Please ahead. your now comes next Lawson from question Peter

Peter Lawson

Thanks so Troy. much

is safety. First question just around

any how's update, strategy XQ and and the safety syndrome, further how you've see differentiation management seen with data much if that? we'd the cases Just going of in

Troy Wilson

you, Thank for Peter, the questions.

mitigation I some have mitigation very We'll to appears from that So to the of it line thing all manage you it seems To point, the that key of an very along. one be high-level syndrome. But very with it. discussed we've be do. we strategy. be to a to it usually the really The data strategy you can profile. they have the consistent keep continued the you you was enhanced question, at be toolkit seen should second differentiation nor much we've given we it that the investigators neither we tell going appears your indication But manage to tolerability. activity. And And tell away exactly and patients it, now safe? of thus the have end, a And if the designed it it's what very differentiation run prior is, syndrome. some encouraging more on far. the we you, we enhanced to line a color given as give have and in the said cut note is, can be effectively? tolerability calls, believe top with release to see robust top what probably see around Ziftomenib it's probably contrary, what And this the what to to can To follow. around need investigators I is clinical We’ll doing to -- and of safety color have safety data. part can

Peter Lawson

may missed see current I of have the carrier the that? readouts we did apologize, this. first trial, head-neck I when but

Troy Wilson

We little vague, question. a me bit were but didn't answer miss it, you your Yes, let Peter.

a end the So to drugs activity. Phase the Alpelisib. us but the focus for this Tipifarnib dose both primary It's X schedule clinical of we tolerability, allows levels The and recommended for to intended looking design trial is determine adjust and that are safety combination. is Bayesian

encouraged. the in be may well commented the I future Peter, are an call. think hope with more or we prepared you share data you and it, at with not-too-distant I will to this opportunity a be we some the haven't others what and opportunity the guidance the Once we going share an but There be put point, trial's there I would around sure we remarks, in be have on that specific venue. it will data to that

Peter Lawson

Great. much. Thanks so

Tom Doyle

Sure.

Troy Wilson

Thank you, Peter.

Operator

Our Suisse. go Please Crédit next ahead. question Fauth of comes from Tiago

Jonathan Ofertiago

thanks Ofertiago, for guys. Hi, question. Jonathan taking our

know So other several and not Ziftomenib to, the a they're Menin trials between about Inhibitor we lot are compared you frequently differentiation already [Indiscernible] running. but

So it Thanks. differentiation those like could of is with or you there in those preclinically about you've so or even from standpoint programs you're those. trial mind, seen far, from relative trials likely anything that what But looks anything between from ahead design? the say of the

Troy Wilson

which dose. data This it's you've the one Phase enrollment. completed was very competitors. making project time, speak will going was something them Ofertiago. on Jonathan of doses, is our highlight different early What addressing XB the just And concern optimist. and dawn Thanks be year the that experience amount to and of very negative I'll was now At as for of is this. X I'm designs. we've FDA the why their for a design in recommended provided positive significant the two which Yeah, lost us I at you the Phase think do time, maybe defer let and perhaps a question. that a I our I'll much to their view ago viewed as is

picture more we to safety, the now look tolerability, the means the at QX, through that it meeting not what will a Phase Ziftomenib Phase that but wasn't it on efficacy should everyone to significant positions a I drugs So think everyone of relative X only have Phase And very presentation those from solid to ultimately the recommended other and give time, at what by medical to in parameters we very pK that That RPXD but be Phase competitively XB others the as X, the are the appreciated going and exposure, the going between the probably follow and get into understanding QX. we've in we're landscape. it difference you're much to confidence full at dose. think seen what That's very in most I perhaps is -- fully the transition doing X. the Jonathan through, the

Jonathan Ofertiago

Thank Helpful. you.

Troy Wilson

Sure.

Operator

from Our question ahead. go comes Jefferies. of Roger Please next Song

Roger Song

can so comment question. Troy, Maybe interaction. the regulatory on Great far just

you the the versus once are will that in XQ the and pivotal, in maybe So data FDA topline RPXD data you be the discussed when plan have discuss four you will with XQ your about later? after

Troy Wilson

Yes, Roger.

want we've want to be say, Phase enrollment and specifics. we to and our don't programs. found all support just it's We're of careful to I the to to sensitivities, that suffice agency the significant of speak the regularly and with the specifics very the work patients on Xb. timing XX it given the much We of across some the here So interact with completed I today needed in be agency them to very partners. productive partnership

in the the to hasn't to needs very timing. much that. that's it's two knows ultimately data happened We the it are don't team Phase the be collecting that to specific submitted FDA to is, the a recommended yet analyzing the and team going dose. that identify to be a require focused needs and package as of lot but process I exactly then that what more to want on to do And

out competitive. Just for is doing urgency respective the the that's and but I agency I only is you, tell process. to I everything need will team clear, and executing this for do, But needed for is to diligence program the not the with their hope they of be really think

Roger Song

it. think well. that seems clinical as we Yes, Got promptly I time removed big last It and [Indiscernible].

at, moving the the Okay. are remind another combo just combo Thank this good the and the study, you're you. the and data monotherapy from can Maybe where if also us, stretch monotherapy, period combo Got this of looks forward. question you just Tipi, going Is us. so for it. -- trial, at to versus you how

Troy Wilson

said up can't And resist. just let me Thanks Roger, because you something pick that Roger. I Yeah, Right. on the question. for

high ago that then. the and ongoing, was in among wasn't There is long don't mind. what I community the with community. If we've the in enrollment exactly we come the underscores now and AML a high AML said, high cohorts time seeing at that that hope the back in clinical that class, investigators in It this level that compound lifted the on back enrolled, you and were thereafter, and and shortly hold engagement interest this we we Ziftomenib. for said interest very schedule engagement of

FTI ourselves that. find Just the wanted answer We an question. round your interesting out Yeah. to On to point. at

So mutant for head directed the the enrollment AIM, seen know neck, the Hrs and is continuing. active. study HN. Tipifarnib the in is Monotherapy which from know data II run in drug registration enrollment you've is We We Phase

see team to Current to of reality the it execute And We to the hard challenges just monotherapy that's is of large different as working IO. on activity. that is is study coursed patients but face, The It platinum both go them the patient that is ways. that typically really a result, coming three sort in and sufficiently to very majority of that study. a addresses have that not to against are that we what a through continue that, fit population.

disregulated populations. The from monotherapy by Alpelisib to combining HRAS the HRAS XX% in you as difference much first population is look open tenfold at is a and population. potential and the the PIKXCA Tipi, when patient potential disregulated you Nearly which X-X% as up

reasons second to due positions course, of biomarkers, by giving screening. additional more you're The is providing

have see streams additional prepared lot we're what team if more Obviously, We're with either pre the remarks, are genetically either that It's I a and win. have and and teams the potential much you drug-drug efficacy open the a up selected that's than but those is a will cohort We this funnel in other. We that top-of-mind by integrate greater a right do it suggests share and being is can that drug good activity the and encouraged quite progress if very screened better that is a of that's for we'll both how final the -- you, monotherapy. regulatory synergy combination share you tolerability, now. the synergistic And could in offer as open have development tell with very there's how drug then you with neck. to them. -clinical is two -- patients helps strong say heard -- Stephen screening. overexpression do will. the and one in don't and very populations hand, for And current more updates had the PIKXCA as aim us development course these really progress acceptable mutations a point patients as at and on data you do who we the just amplifications tell HRAS are You have on making -- the current is you you Kura question, we much it on it. can safety engaged in

Roger Song

comprehensive the Alex, for Thanks thank you. Great. comments

Troy Wilson

you. Thank

Operator

Our comes next Reni Securities. ahead. Go from JMP question of Benjamin

Reni Benjamin

taking the starting just good Hey, for questions. off afternoon, guys, Maybe thanks with Ziftomenib.

continue any have get -- I was still that get talked started? you'd think, clinical thoughts, one your top we've or preclinical looking are when you there changes combination potential studies the started? studies, what about you think curious, others. And progress to potential do are might like development, you X to been that to in the of were both as combination and I'm [Indiscernible] past through the partners. the just some There

Troy Wilson

Ren, in of packed for the there. Yes. lot thanks question. sort a There's

want of Inhibitor can the Combinations to provide to see be me probably the greatest for Ultimately, Let and best it. us. high serve s highest interest I need. if that's to most unpack you if patients Menin unmet going are the use

combinations. predicate I believe is where monotherapy recommended course, those The of combinations, think X start any strong of identification that there's you for but very to of registration, one disease will so paradigm case to dose combo. the will a a treatment know be be AML be -- to there's made a the to very the of -- Phase with a continuing

studies, completed enrollment the of are Ren on with activities, background topline quarter. goal that the toward on and in a combination due -- to lot data giving moving earlier There of the we've to we're therapy. going the forward are speed support and We next all in frontline lines both we've in now looking just

said haven't when to on going timing it's We we actively appropriate and again, very the studies the want we'll that can I But those assure a agency. are about are lot respectful with background interactions in and of more you underway. be because activities the say yet

There's terms of couple evidence put I mean, least strong In very be synergy partner. between for a prioritizing to them, attractive them, finger your you on potential Venetoclax Venetoclax and continues of over at combination Ziftomenib. a some running There's a a a for strong suggestions do into substitute Obviously, but clinically think rationale we that that patients. study, carry synergy I may very that's not have there's that. to

patient of you. three. a meeting. a of those for target patients Well, Foot types efficient. outside opportunities of forward meant be is continuation as comprehensive, what course a later genetic get it development I think year our well meant we to both population. find to It's Probably looking When other we're The looking to we've it's in it's as large very medical to strategy, sub sub the threes genetic and is little with you'll as the unveil the done. we flit it's expansion types, closer sharing in to

color approaching. very here some as share, you the gives quickly we're and that in much I hopefully second to more So half think which

Reni Benjamin

just Maybe perfect. gears That's Got it. just too Tipi. from switching

next the combination. first had The study with in current a

to going HRAS be cohort. You're of starting enrollment the overexpression

bypass as prognostic get that alpha? for cohort? target there PIXK this has patient population who rationale? other Tipi, a being factors. overexpression a worse is a it a to exposed How for patients outside that Or any we of are so mechanism viewing should be much it they Is patients And

Troy Wilson

Yeah.

in Ren, it's you great I'm going them. So a each answer them and tease and -- really of to to questions it's good and just question, a have apart there,

target. in So relate draw afternoon there updated just is very trial then, a in of a farnesylated targets. Where corporate to X graphic there's major the I'll that farnesylated attention, are everybody's And with rev connection mechanism, farnesylation. expression. the both to our at call, populations is HRAS presentation And HRAS that we this second least shows Tipifarnib which over current and relevance that nice this

then question, kinase which But bypass the the regulation So at there's and reasons, on forward graphics XX And worked It what it's context inhibit next times kinase often you very deletes think potentially the this protein, is we those group down. principal presentation. to a inhibitors. rationale doing PIX for That's Once strong bypass XX or removing strong But for one rationale TOR resistance. for Tipifarnib your And everyone we of the resistance kinase look our I is actor team's that in the not where in years -- direct in PIKXCA to exactly a we And Ren, Ren, That's and think bad it's you're if up which you're future. in you'll you in reasons, and ago blocks mechanisms. again, addressing the if sharing that HRAS a job RAS, see is node with rep. a mentioned corporate mutated. a silences overexpressers of think of with you're you TOR, the you of a The Personally, alpha. populations, terrific see the we inhibitors the just lot would even interested I PIX that. in directly resistance. off tore results rev, Darnesyl anchor why combination. through

Reni Benjamin

of final How trial, you to just mechanism Kind or the that highlighted have overall the looking really the at work little might response looking survival preclinical I rate free of bit as would you the it primarily? actually the at study like action? ACR. Can goals decision like talk of question prevent might a things Would is My and mutations? current be mainly, of at no-go, what that might be go it. be resistant was progression you kind be metrics lung

Troy Wilson

really record Ren. current three question, in corporate it distill broken on like And speak our now or slides direct everyone that Great sound four there our available here, to There but a I would that long, Yeah. essence. are Right. it to its to website. again, and down revised presentation that's

is cells subpopulation you called EGFR quickly of Ren, those it as cells protein. are protein. tolerant farnesylated they action drug-tolerant treat farnesylated They tumors, those drug-tolerant your let's a which is well-understood on actually cells, of by they are just -differentiate So lug actually state and drug lung depends through The that fraction reason The are that on by The enter mechanism that architecture. a state questions. cells. DTC now are a cells depends rewire tolerant process there process mutant they jog which small A of their cells. tumors de Osimertinib. drug so with when become that drug-tolerant The tumors they cellular exit

If you bar and the block essentially door. exit, entry the you

seed drug Now become find are those state and then they In It DCTTC DTC that cells those Osimertinib. is allow cells, resistance. believed they your that question next cook you don't eventually pressure to tolerant to can state, from Ren die adaptive enter molecular a those the susceptible, off their and essentially they under and to around sit origins there of Osimertinib. way

the In osimertinib and of the ever allow that, alone, don't the And the relapse. there. you you of next the point sales to and I'll the again, see corporate data presentation. to then tumor the in on case eventually consequence get So slide cartoon the you

In You're grow resistance. In need question, to at on third-party osimertinib, these for delay prevention, two they double resistance, you of see the your to looking, complete for safety boom, dose To we you're way. but prevention, a seeds be when you little Phase pre is the get a establish data. are an back. -- then endpoint, and what cases, comes you're recommended What looking the some Ren, where adding that primary at along combination. are the a And in -clinical and current Tipifarnib the number case You extended course you nearly -- looking out tumor going for? we're PFS lung? tolerability, a of endpoints to are of looking the the

using you the, clinical all -- and very monotherapy see pretty as data see the -- is sharing activity to optimistic to coming years you a Given the hope I've of the recapitulate rate. in concept Alpelisib we're This trial is obviously, provide various could the as just We're with if trial clinical that, see third whether And example. forward using the this the a strength you'll the I and you'll I after fourth, it and of is look up high-quality have that. answered the the cautiously the hope response then several you'd think preclinical Ren. updates of the I question. with parts a this a precision difference it's a and real high first -- And that's to make is see see see pre patient and medicine longer go you'll is significant I'll populations, much this life this on -clinically, designed recapitulates Tipi we osimertinib Osimertinib But just precision all for data a medicine. future. and big really exciting to we of final and patients of OCTP that to now what we larger PFS be much hope have but the what strong comment -- of for data. keep because then in second. look your to deal I an going if them

Reni Benjamin

Have you so for one. definitely You Thank very backing much have. it nicely. good

Troy Wilson

Sure. Thanks, Ren.

Operator

come Privitera Please go ahead. next [Operator instructions] from Eva of At question Cowen. this will time our

Eva Privitera

and taking Thanks for questions enrollment. congrats on completing our the

(ph). you've you So that earlier additional mentioned cases seen DF of

severity what at with Just What up on wanted few and to follow a the dose? details. that was

Troy Wilson

question. The Eva -- pure appear between in -- dose Phases a syndrome see more to doesn't to a two differentiation syndrome step is differentiation to comment with back. least differentiation be Xb of expects burden, Starting and Thanks the severity the appears a extent our this maybe the there with The dependent. mechanism. One more tumor related for take there KMTXA. experience, be at cohorts, maybe doesn't to Yes. among just dose, to patient-specific,

experience seeing such clinical able with usually a have really has strategy either differentiation that's the been, mitigation syndrome. again, if have We the enhanced to to a been syndrome, But activity. the hard to of need our ultimately differentiation they draw number. differentiation you're conclusions. that has marker and be manage any our toolkit that And physicians small It's experience definitive

can. it's it that. making we've in we've if a very the And again, have the found give They're I'm it and they happy past they investigators we thorough leaning now talked patients than they're I through have about need. the they summarize to but to mitigation can sure strategy helpful, expert tools -- enhanced them so what that the that and into is with that the get

XXX mechanism is isn't this be out X Phase we determination part to whether it's or any really, of of going to recommended with it the But watch think, XXX milligrams So for the dose. action. milligrams of something

Eva Privitera

other same the that's helpful the RPXD that together just confirm you, time? and at one and of the will top be nomination Thank to point line data disclosed that

Troy Wilson

Yes. Yes.

Eva Privitera

And Okay. -- expect we can

Troy Wilson

Yes

Eva Privitera

Any or to additional RPXD disclosure support rationale? PKPD with any data along the new

Troy Wilson

we'll support meeting. want the that presentation know data sanctity we for dose. line to eventual X to the Suffice get say a it don't protect either the I set data the into in up Phase the of make of of because medical sure we PKPD ultimate recommended all will at

the is, thing efficacy questions. a of to continue a you And They're the and matter probably can elements think seeing of are and successful that will what safety going data. gives again does. top-line level that you it be going now tell are that. be confidence clinical And does Phase This is, in tolerability to is I I the X. you

fulsome too. able like medical where presentation you be and more be exposure get a QX into that the very it'll I are meeting the of to kinds things think in will getting questions at

Eva Privitera

you Thank much. it. so Got

Troy Wilson

Thank you.

Operator

time this up. At session. question-and-answer our concludes That

over Wilson conference any to closing Troy turn for Now, let's the Mr. back remarks.

Troy Wilson

We'll call you Operator. sciences the you, in Jefferies life thank again the Innovation joining forward me.Thank everyone. and many any questions, if Tom, look a evening, Pete, free seeing you please good there. contact In the to have feel you again, today. once Thank Cowen meantime, our be Healthcare have we for Oncology or Summit. in and month additional JMP participating And Conference to The you all next conference of

Operator

concluded. The conference today's Thank presentation. attending you now has for

now may You disconnect.

Kura Oncology (KURA) 5 May 222022 Q1 Earnings call transcript